"R&D Trends: Allergic Rhinitis - Immunotherapy dominates the pipeline" - New Market Report
The 2012 pipeline shows continued strong interest in immunotherapy, which makes up 43% of products in development. Advancements in clinical trials and key partnerships are increasing exposure of this class. In this largely stable market, areas of innovation exist with nasal antihistamine/corticosteroid combinations showing progress, while a number of novel targeted therapies raise skepticism.
View full press release